Please assess the completion status of the following clinical trial:

Trial Title: Sleep and Endometrial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be women at least 18 years old~* have clinical indications of primary endometrioid adenocarcinoma of the endometrium~* be scheduled for staging surgery by laparotomy under standardized protocols~* have the ability to communicate in English sufficient for completion of study materials~* have no neuromuscular/ movement disorders (for actigraphy purposes)~* have no uncontrolled medical, sleep, endocrine or psychiatric illness (as determined by their attending physician as part of clinical care)~* have no ongoing use of medication known to affect sleep or wake function (e.g., hypnotics, benzodiazepines, antidepressants, anxiolytics, antipsychotics, decongestants, sedating antihistamines, beta blockers, corticosteroids)~Exclusion Criteria:~* have a history of previous or concomitant cancer~* have an estimated life expectancy of \< 6 months~* will be admitted to the hospital prior to the day of surgery~* are unable to complete study measures~* are unable to provide meaningful informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zolpidem (Type: EXPERIMENTAL): Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women \> or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
- sugar pill (Type: PLACEBO_COMPARATOR): Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).